CHAMBERLAIN UNIVERSITY NR565
EXAM \ NR565 ADVANCED
PHARMACOLOGY MIDTERM EXAM
2026/2027 AND STUDY
EXAM
1. A 75-year-old patient reports that their once-daily
medication seems to be causing side effects that last longer
than expected. What pharmacokinetic change is the most
likely cause?
A. Increased gastric motility
B. Increased first-pass effect
C. Decreased renal excretion
D. Increased protein binding
Answer: C. Decreased renal excretion.
Rationale: Age-related decline in glomerular filtration rate (GFR)
leads to decreased drug clearance, prolonging half-life and
increasing the duration of action and risk of toxicity.
2. A patient with liver failure is prescribed a prodrug. The
nurse practitioner anticipates that the therapeutic effect of
this drug will be:
A. Enhanced
B. Diminished
C. Unchanged
D. Rapidly toxic
Answer: B. Diminished.
Rationale: A prodrug requires hepatic metabolism (often via
,CYP450 enzymes) to convert to its active form. Liver failure
impairs this conversion, reducing efficacy.
3. Which statement best describes the mechanism of a
CYP450 enzyme inducer?
A. It inhibits the metabolism of other drugs, leading to toxicity.
B. It increases the synthesis of metabolic enzymes, reducing serum
levels of other drugs.
C. It blocks drug absorption in the small intestine.
D. It increases renal tubular reabsorption.
Answer: B. It increases the synthesis of metabolic enzymes,
reducing serum levels of other drugs.
Rationale: Inducers (e.g., carbamazepine, rifampin) upregulate
enzyme production, causing co-administered drugs to be
metabolized faster, often leading to subtherapeutic effects.
4. A patient taking warfarin (CYP2C9 substrate) starts taking
rifampin. What adjustment is likely necessary?
A. Decrease the warfarin dose
B. Increase the warfarin dose
C. No change is needed
D. Switch warfarin to a direct thrombin inhibitor
Answer: B. Increase the warfarin dose.
Rationale: Rifampin is a potent CYP450 inducer. It will increase
the metabolism of warfarin, lowering the INR and requiring a
higher dose to maintain therapeutic anticoagulation.
5. Grapefruit juice is a known inhibitor of CYP3A4. If a patient
drinks grapefruit juice while taking simvastatin, the NP
should monitor for:
A. Decreased cholesterol lowering
,B. Increased risk of myopathy (muscle pain/rhabdomyolysis)
C. Increased blood pressure
D. Decreased liver function tests
Answer: B. Increased risk of myopathy.
Rationale: Inhibition of CYP3A4 decreases the metabolism of
simvastatin, leading to higher serum concentrations and an
increased risk of statin-induced myopathy and rhabdomyolysis.
6. A drug with a narrow therapeutic index is prescribed. This
means:
A. The drug has a wide safety margin.
B. There is a small range between the effective dose and a toxic
dose.
C. The drug requires no monitoring.
D. The drug is only available intravenously.
Answer: B. There is a small range between the effective dose and
a toxic dose.
Rationale: Narrow therapeutic index drugs (e.g., warfarin, lithium,
digoxin) require careful monitoring because small changes in dose
or metabolism can result in toxicity or treatment failure.
7. A neonate is receiving a medication that is primarily
metabolized by the liver. Compared to an adult, the neonate
is at higher risk for toxicity because:
A. Hepatic enzyme systems are immature.
B. Glomerular filtration rate is increased.
C. Protein binding is increased.
D. Gastric pH is neutral.
Answer: A. Hepatic enzyme systems are immature.
Rationale: In neonates, the CYP450 enzyme system is not fully
, developed for the first few months of life, significantly reducing
the ability to metabolize drugs.
8. Which pharmacodynamic change is commonly observed in
the geriatric population?
A. Increased sensitivity to beta-adrenergic agonists
B. Decreased sensitivity to anticoagulants
C. Increased sensitivity to benzodiazepines and opioids
D. Decreased sensitivity to anticholinergic medications
Answer: C. Increased sensitivity to benzodiazepines and opioids.
Rationale: Age-related changes in receptor binding and central
nervous system (CNS) physiology make older adults more
susceptible to the CNS depressant effects of benzodiazepines and
opioids, increasing the risk of falls and respiratory depression.
9. The half-life of a medication is 12 hours. Approximately
how long will it take for the drug to reach steady state?
A. 12 hours
B. 24 hours
C. 60 hours (2.5 days)
D. 120 hours (5 days)
Answer: C. 60 hours (2.5 days).
Rationale: Steady state is typically achieved after 4 to 5 half-lives.
5 x 12 hours = 60 hours.
10. A patient is prescribed Drug A, which is 95% protein
bound. The patient starts Drug B, which is highly protein
bound and displaces Drug A. The NP should monitor for:
A. Decreased effect of Drug A
B. Increased effect/toxicity of Drug A
C. No change in Drug A levels
EXAM \ NR565 ADVANCED
PHARMACOLOGY MIDTERM EXAM
2026/2027 AND STUDY
EXAM
1. A 75-year-old patient reports that their once-daily
medication seems to be causing side effects that last longer
than expected. What pharmacokinetic change is the most
likely cause?
A. Increased gastric motility
B. Increased first-pass effect
C. Decreased renal excretion
D. Increased protein binding
Answer: C. Decreased renal excretion.
Rationale: Age-related decline in glomerular filtration rate (GFR)
leads to decreased drug clearance, prolonging half-life and
increasing the duration of action and risk of toxicity.
2. A patient with liver failure is prescribed a prodrug. The
nurse practitioner anticipates that the therapeutic effect of
this drug will be:
A. Enhanced
B. Diminished
C. Unchanged
D. Rapidly toxic
Answer: B. Diminished.
Rationale: A prodrug requires hepatic metabolism (often via
,CYP450 enzymes) to convert to its active form. Liver failure
impairs this conversion, reducing efficacy.
3. Which statement best describes the mechanism of a
CYP450 enzyme inducer?
A. It inhibits the metabolism of other drugs, leading to toxicity.
B. It increases the synthesis of metabolic enzymes, reducing serum
levels of other drugs.
C. It blocks drug absorption in the small intestine.
D. It increases renal tubular reabsorption.
Answer: B. It increases the synthesis of metabolic enzymes,
reducing serum levels of other drugs.
Rationale: Inducers (e.g., carbamazepine, rifampin) upregulate
enzyme production, causing co-administered drugs to be
metabolized faster, often leading to subtherapeutic effects.
4. A patient taking warfarin (CYP2C9 substrate) starts taking
rifampin. What adjustment is likely necessary?
A. Decrease the warfarin dose
B. Increase the warfarin dose
C. No change is needed
D. Switch warfarin to a direct thrombin inhibitor
Answer: B. Increase the warfarin dose.
Rationale: Rifampin is a potent CYP450 inducer. It will increase
the metabolism of warfarin, lowering the INR and requiring a
higher dose to maintain therapeutic anticoagulation.
5. Grapefruit juice is a known inhibitor of CYP3A4. If a patient
drinks grapefruit juice while taking simvastatin, the NP
should monitor for:
A. Decreased cholesterol lowering
,B. Increased risk of myopathy (muscle pain/rhabdomyolysis)
C. Increased blood pressure
D. Decreased liver function tests
Answer: B. Increased risk of myopathy.
Rationale: Inhibition of CYP3A4 decreases the metabolism of
simvastatin, leading to higher serum concentrations and an
increased risk of statin-induced myopathy and rhabdomyolysis.
6. A drug with a narrow therapeutic index is prescribed. This
means:
A. The drug has a wide safety margin.
B. There is a small range between the effective dose and a toxic
dose.
C. The drug requires no monitoring.
D. The drug is only available intravenously.
Answer: B. There is a small range between the effective dose and
a toxic dose.
Rationale: Narrow therapeutic index drugs (e.g., warfarin, lithium,
digoxin) require careful monitoring because small changes in dose
or metabolism can result in toxicity or treatment failure.
7. A neonate is receiving a medication that is primarily
metabolized by the liver. Compared to an adult, the neonate
is at higher risk for toxicity because:
A. Hepatic enzyme systems are immature.
B. Glomerular filtration rate is increased.
C. Protein binding is increased.
D. Gastric pH is neutral.
Answer: A. Hepatic enzyme systems are immature.
Rationale: In neonates, the CYP450 enzyme system is not fully
, developed for the first few months of life, significantly reducing
the ability to metabolize drugs.
8. Which pharmacodynamic change is commonly observed in
the geriatric population?
A. Increased sensitivity to beta-adrenergic agonists
B. Decreased sensitivity to anticoagulants
C. Increased sensitivity to benzodiazepines and opioids
D. Decreased sensitivity to anticholinergic medications
Answer: C. Increased sensitivity to benzodiazepines and opioids.
Rationale: Age-related changes in receptor binding and central
nervous system (CNS) physiology make older adults more
susceptible to the CNS depressant effects of benzodiazepines and
opioids, increasing the risk of falls and respiratory depression.
9. The half-life of a medication is 12 hours. Approximately
how long will it take for the drug to reach steady state?
A. 12 hours
B. 24 hours
C. 60 hours (2.5 days)
D. 120 hours (5 days)
Answer: C. 60 hours (2.5 days).
Rationale: Steady state is typically achieved after 4 to 5 half-lives.
5 x 12 hours = 60 hours.
10. A patient is prescribed Drug A, which is 95% protein
bound. The patient starts Drug B, which is highly protein
bound and displaces Drug A. The NP should monitor for:
A. Decreased effect of Drug A
B. Increased effect/toxicity of Drug A
C. No change in Drug A levels
